DEFR14A: NAYA Biosciences Postpones Annual Meeting, Amends Proxy Statement

NAYA Biosciences has postponed its 2024 Annual Meeting of Stockholders to April 9, 2025, and filed an amended proxy statement due to insufficient votes on special proposals.

Summary

• NAYA Biosciences has postponed its 2024 Annual Meeting of Stockholders to April 9, 2025.
• The company filed an amended proxy statement on March 12, 2025, superseding the original proxy statement filed on February 11, 2025.
• The postponement was due to the Standard Proposals receiving sufficient votes for approval, while several Special Proposals had not garnered the necessary votes.
• The Standard Proposals include the election of five directors and the ratification of M&K CPAS, PLLC as the independent registered public accounting firm for the fiscal year ended December 31, 2024.
• The Special Proposals involve the issuance of common stock upon conversion of preferred stock and debentures, an amendment to the stock incentive plan to increase the number of shares available for issuance to 8,200,000 (pre-reverse split), and an amendment to the articles of incorporation to increase the number of authorized shares of common stock from 50,000,000 to 100,000,000 after a reverse split.
• The new record date for the Annual Meeting is March 10, 2025, and all votes cast prior to the postponement are null and void.
• Stockholders are being asked to vote again on the Standard Proposals using a new proxy card.
• The Annual Meeting will be held virtually at www.virtualshareholdermeeting.com/NAYA2024 at 12:00 p.m. Eastern Time.

Sentiment

Score: 5

Explanation: The document is neutral in tone, primarily conveying factual information about the postponement of the annual meeting and the amended proxy statement. The postponement itself could be seen as slightly negative, but the company is taking steps to address the situation.

Positives

• The company is taking steps to ensure all proposals are properly considered by stockholders.
• The company is providing clear instructions on how stockholders can vote.
• The company is committed to good corporate governance practices by submitting the selection of its independent registered public accounting firm for ratification by the stockholders.

Negatives

• The postponement of the Annual Meeting may cause uncertainty among investors.
• The need to re-vote on the Standard Proposals may be inconvenient for stockholders.
• Several Special Proposals had not garnered the necessary votes required for approval.

Risks

• Failure to obtain stockholder approval for the Special Proposals could impact the company's ability to raise capital and execute its business plan.
• The potential reverse stock split could negatively impact the stock price.
• The company's reliance on smaller reporting company exemptions may limit transparency for investors.

Future Outlook

The company is seeking stockholder approval for several proposals that are critical to its future operations and financial flexibility.

Industry Context

The postponement of the annual meeting and the need for an amended proxy statement highlight the challenges that smaller companies face in obtaining stockholder approval for complex proposals.

Comparison to Industry Standards

• The director compensation program is designed to align with the long-term interests of stockholders, which is a common practice in the industry.
• The company's corporate governance practices, such as having independent directors and audit, compensation, and nominating and governance committees, are consistent with industry standards.
• The company's hedging policy, which prohibits directors, officers, and employees from hedging company securities, is a common practice to prevent conflicts of interest.

Related Party Transactions

• In the fourth quarter of 2022, the Company issued a series of demand promissory notes in the aggregate principal amount of $550,000 to a related party, JAG, a company in which the Company's Chief Financial Officer is a beneficiary but does not have any control over its investment decisions with respect to the Company, for an aggregate purchase price of $500,000.
• On July 10, 2023, the Company issued an additional demand promissory note in the principal amount of $110,000 to JAG for a purchase price of $100,000.
• In the fourth quarter of 2022, the Company issued demand promissory notes in the aggregate principal amount of $220,000 for an aggregate purchase price of $200,000, of which (1) $100,000 was received from its Chief Executive Officer and (2) $100,000 was received from an entity controlled by its Chief Financial Officer.
• Legacy NAYA and Cytovia, entered into a loan agreement on August 1, 2023, pursuant to which Cytovia made available to Legacy NAYA a term loan for up to $1,000,000, bearing interest at a rate of 5% per annum.
• On October 18, 2023, Legacy NAYA entered into an asset purchase agreement with Cytovia Therapeutics Holdings, Inc. and Cytovia Therapeutics, LLC (collectively, Cytovia) to acquire the rights to the two bifunctional antibodies CYT303 and CYT338 (now known as NY-303 and NY-338).

Stakeholder Impact

• Stockholders are impacted by the postponement of the Annual Meeting and the need to re-vote.
• Employees may be impacted by the potential changes to the stock incentive plan.
• The company's ability to execute its business plan and raise capital could impact all stakeholders.

Next Steps

• Stockholders should review the amended proxy statement and vote on the proposals.
• The company will hold the Annual Meeting on April 9, 2025.
• The company will announce the voting results in a current report on Form 8-K.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Auditor, Common Stock, Preferred Stock, Reverse Stock Split, NAYA Biosciences